Stream
Stories
-
Medtronic announces preliminary results of MiniMed exchange offer
Medtronic says its exchange offer to swap MiniMed shares for Medtronic ordinary shares was oversubscribed, with 298,024,452 Medtronic shares tendered. Medtronic intends to accept 55,032,401 shares for 252,813,348 MiniMed shares, estimating about 18.3% of tendered shares will be exchanged.
-
Bristol Myers Squibb partners with Saudi Schizophrenia Association to launch Small Wins initiative
BMS and the Saudi Schizophrenia Association ('Ehtiwaa') collaborated to distribute more than 70 personalized Small Wins toolkits in Riyadh to support people living with schizophrenia. The kits guide patients through four steps-pick a card, try an activity, recognize the win, and add it to a Small Wins jar-to boost daily engagement and self-esteem.
-
NOPARK trial reports nicotinamide riboside does not improve clinical outcomes in Parkinson disease
The authors reported that among 393 participants, the total MDS-UPDRS score increased by 2.45 points with nicotinamide riboside and decreased by 0.27 points with placebo, yielding an adjusted mean difference of 2.72 points favoring placebo. Non-motor symptom burden worsened more with nicotinamide riboside, with an adjusted mean difference of 4.22 points.
-
RINGSIDE Phase II Study of Varegacestat for Desmoid Tumors
The authors reported that 42 participants were randomized to three dose regimens of varegacestat, with median tumor volume reductions at week 16 of -51.91%, -15.25% and -9.50% for the 1.2-mg once-daily, 2-mg intermittent and 4-mg intermittent doses, respectively. In the open-label extension, 29 participants received 1.2-mg once-daily and achieved a median best tumor volume change of -85.88% and a confirmed objective response rate of 57.1%.
-
Lilly releases new exploratory data from TOGETHER-PsO Phase 3b trial
The company announced exploratory biomarker data from the TOGETHER-PsO Phase 3b study showing broader immune and metabolic changes when Taltz (ixekizumab) and Zepbound (tirzepatide) were used together versus Taltz alone. The analysis reported 482 versus 140 differentially expressed proteins and 467 versus 16 genes at Week 36, with greater reductions in inflammatory immune activity.
-
BioMarin presents new VOXZOGO data at ASBMR 2026
BioMarin will present new data from 13 studies, including a randomized, double-blind, placebo-controlled trial on VOXZOGO's effect on foramen magnum and craniocervical junction growth in children with achondroplasia. The company will also share data on the investigational long-acting medicine BMN 333 and on VOXZOGO's potential use in hypochondroplasia, for which it has submitted a supplemental New Drug Application.
-
FDA finalizes guidance on post-approval manufacturing changes to biosimilars
FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance.
-
FDA final rule permits salt substitutes in standardized foods
The rule, effective December 14, 2026, amends FDA's standards of identity to permit the use of salt substitutes in standardized foods. The change is intended to reduce sodium content in these foods.
-
FDA approves Hovilpri for immunocompromised patients with HSV lesions
The FDA approved Hovilpri (pritelivir) tablets for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus and have not responded to acyclovir, valacyclovir, or famciclovir. In a Phase 3 trial, 63% of patients treated with Hovilpri had all lesions healed by 28 days versus 34% with other medications.
-
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management
The study, titled SUNRISE 1, is a Phase 3 randomized, double-blind, placebo-controlled trial of VK2735 administered orally for weight management. It plans to enroll 560 participants starting October 15, 2026, with primary completion projected for July 2028.
-
FrieslandCampina registers Phase 3 trial of infant formula with bio-active ingredients
The study was first posted on ClinicalTrials.gov on October 9, 2026, and plans to enroll 387 participants with a start date of January 2027. It aims to compare growth, immune parameters, and gut health between infants receiving the investigational formula and those receiving a control formula.
-
Viking Therapeutics registers Phase 3 trial of VK2735 for weight management in type 2 diabetes
The study plans to enroll 560 participants and is expected to begin on October 16, 2026. It plans to evaluate oral VK2735 for weight management in adults with type 2 diabetes who are obese or overweight.